Emergent BioSolutions Q4 2023 Adj EPS $(0.770) Misses $(0.190) Estimate, Sales $276.600M Miss $293.533M Estimate
Portfolio Pulse from Benzinga Newsdesk
Emergent BioSolutions (EBS) reported Q4 2023 adjusted EPS of $(0.770), missing the $(0.190) estimate, with sales of $276.600M also missing the $293.533M estimate. This represents a 16.36% decrease in sales compared to the same period last year.

March 06, 2024 | 9:19 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Emergent BioSolutions reported a significant miss in both adjusted EPS and sales for Q4 2023, with a notable year-over-year decrease in sales.
The significant miss in both EPS and sales estimates, coupled with a substantial year-over-year decrease in sales, is likely to negatively impact investor sentiment and the stock price of EBS in the short term. The magnitude of the miss in EPS, exceeding 300%, and the sales miss, although smaller, are critical factors that investors will likely react to negatively.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100